[1] Shweta Urva, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending...
[1] Shweta Urva, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 2022; 400: 1869–81. [2] Timo D. Müller et al. ...
3.首个治疗2型糖尿病的GIP和GLP-1双重受体激动剂:替尔泊肽. 4.https://kns.cnki.net/kcms/detail//31.1746.R.20230214.1724.004.html 5.https://doi.org/10.1056/NEJMoa2107519 6.Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist.doi.org/10.1016/j.hsr....
[0032] 所述 “胰高血糖素/GLP ‑1/GIP三重激动剂 (Glucagon/GLP‑1/GIP triple agonist)”可以与“GCG/GLP‑1/GIP三重激动剂”、“GCG/GLP‑1/GIP受体三重激动剂”、“GCG受 体、GLP‑1受体,以及GIP受体三重激动剂”、“GCGR/GLP‑1R/GIPR三重激动剂”、“三重激动 剂”,或“对胰高血糖...
其他被建议用于肥胖或超重的糖尿病患者的药物则需要在医生指导下使用,如:GLP-1受体激动剂(glucagon-like peptide-1 receptor agonist, GLP-1RA)、钠-葡萄糖协同转运蛋白 2(sodium glucose cotransporter 2, SGLT-2)抑制剂被建议用于肥胖或超重的糖尿病患...
3.首个治疗2型糖尿病的GIP和GLP-1双重受体激动剂:替尔泊肽. 4.https://kns.cnki.net/kcms/detail//31.1746.R.20230214.1724.004.html 5.https://doi.org/10.1056/NEJMoa2107519 6.Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist.doi.org/10.1016/j.hsr....
A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiomeGLP-1GLP-2Gut-liver axisNAFLDNASHCurrently there is no FDA-approved drug to treat nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), rates of ...
agonist:激动剂 incretin:肠降血糖素 mimetic:/mɪˈmetɪk/类似物 analog:类似物 These medications are relatively new. The U.S. Food and Drug Administration (FDA) approved the first GLP-1 agonist (exenatide) in 2005. Researchers are still learning about their other potential uses and benefit...
1.M. Yu, et al., Battle of GLP-1 delivery technologies, Adv. Drug Deliv. Rev. (2018), 2.Lijing Wang, Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP Drug Design, Drug Design, Development and Therapy 2022:16 1547–1559...
[1] Kalra S, Sahay R. A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. Diabetes Ther. 2020 Sep;11(9):1965-1982. [2]Lenharo M. How blockbuster obesity drugs create a full feeling - even before one bite of food. Natu...